Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Abbott Receives FDA Approval For Its Tactiflex™ Duo Ablation Catheter To Treat People ...

8 September 2026 · By · Wire by Fusion42

Published

8 September 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 8 September 2026 · Fusion42 review

Abbott has received FDA approval for its Tactiflex™ Duo Ablation Catheter, a device used to treat patients with abnormal heart rhythms, enabling it for use in the United States healthcare market.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 31 Aug 2026 and 8 Sep 2026.

◆ ◆ The Wire takeaway

This FDA approval opens US market access for medical device startups focused on cardiac ablation. You can now pitch hospitals and clinics on new catheter-based treatments competing with Abbott's cleared device.

◆ Coverage

3 sources · first reported 31 Aug 2026 · latest 8 Sep 2026

◆ Related on Wire

◆ Topics

MedtechFDA-approvalablation-catheterheart-rhythmmedical-deviceUS-market